Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Promacta (eltrombopag) is known as Revolade® outside the U.S. and is marketed worldwide by Novartis.
It is a thrombopoietin receptor agonist. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals and is transferred to Nova...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion